Abbott Laboratories Corporation

Abbvie Inc.

Icahn School of Medicine at Mount Sinai

Abb Vie Deutschland Gmbh & Co. Kg

Robert N Ziemann

David J Hawksworth

Bryan C Tieman

Bailin Tu

Susan E Brophy

Joan D Tyner

Larry G Birkenmeyer

A Scott Muerhoff

Christopher C Marohnic

April Ahlberg

Kathy Otis

Robert William Siegel

Carol S Ramsay

Anthony Scott Muerhoff

Dinesh O Shah

Barry Lee Dowell

Mary S Pinkus

Cheng Zhao

Carolyn J Strobel

Philip M Hemken

Michael White

Frank C Grenier

James W Scheffel

Robin A Gutierrez

Dagang Huang

Jeffrey M Werneke

Suresh M Desai

Saul A Datwyler

Bernhard K Mueller

Qiaoqiao Ruan

Sergey Y Tetin

Samar Kumar Kundu

Ryan F Workman

Andreas Popp

Gangamani S Beligere

Elaine Marie Brate

Andrea Branch

Edward T Olejniczak

Lowell J Tyner, Legal Representative

Dominick L Pucci

Sharmila Manoj

Zhiguang Yu

Francis Eng

David C Sogin

Don M Laird

Lianli Chi

Shamila Manoj

Joan D(deceased) Tyner

Bryan Tieman

Barry L Dowell

James Scheffel

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.

Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies

Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.

Anti-GP73 monoclonal antibodies and methods of obtaining the same

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.

The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of

[object Object]

The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.

HCV core lipid binding domain monoclonal antibodies

Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.

Composition and method for the diagnosis and treatment of iron-related disorders

The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.

Antibodies to troponin I and methods of use thereof

The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.

Antibodies that bind to mammalian NGAL and uses thereof

The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.

PlGF-1 assay and kits and components thereof

Growing community of inventors

Lindenhurst, IL, United States of America

Robert N Ziemann